Literature DB >> 9927403

Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments].

M F Fromm1, R B Kim, C M Stein, G R Wilkinson, D M Roden.   

Abstract

BACKGROUND: Although quinidine is known to elevate plasma digoxin concentrations, the mechanism underlying this interaction is not fully understood. Digoxin is not extensively metabolized, but it is known to be transported by the drug efflux pump P-glycoprotein, which is expressed in excretory tissues (kidney, liver, intestine) and at the blood-brain barrier. Accordingly, we tested the hypothesis that inhibition of P-glycoprotein-mediated digoxin transport by quinidine contributes to the digoxin-quinidine interaction. METHODS AND
RESULTS: First, we demonstrated active transcellular transport of both digoxin and quinidine in cultured cell lines that express P-glycoprotein in a polarized fashion. In addition, 5 micromol/L quinidine inhibited P-glycoprotein-mediated digoxin transport by 57%. Second, the effect of quinidine on digoxin disposition was studied in wild-type and in mdr1a(-/-) mice, in which the gene expressing the major digoxin-transporting P-glycoprotein has been disrupted. Because the in vitro data showed that quinidine itself is a P-glycoprotein substrate, quinidine doses were reduced in mdr1a(-/-) mice to produce plasma concentrations similar to those in wild-type control animals. Quinidine increased plasma digoxin concentrations by 73.0% (P=0.05) in wild-type animals, compared with 19.5% (P=NS) in mdr1a(-/-) mice. Moreover, quinidine increased digoxin brain concentrations by 73.2% (P=0.05) in wild-type animals; by contrast, quinidine did not increase digoxin brain concentrations in mdr1a(-/-) mice but rather decreased them (-30.7%, P<0.01).
CONCLUSIONS: Quinidine and digoxin are both substrates for P-glycoprotein, and quinidine is a potent inhibitor of digoxin transport in vitro. The in vivo data strongly support the hypothesis that inhibition of P-glycoprotein-mediated digoxin elimination plays an important role in the increase of plasma digoxin concentration occurring with quinidine coadministration in wild-type mice and thus support a similar mechanism in humans.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9927403     DOI: 10.1161/01.cir.99.4.552

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  68 in total

Review 1.  Drug interactions and the statins.

Authors:  R J Herman
Journal:  CMAJ       Date:  1999-11-16       Impact factor: 8.262

2.  Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.

Authors:  R B Kim; C Wandel; B Leake; M Cvetkovic; M F Fromm; P J Dempsey; M M Roden; F Belas; A K Chaudhary; D M Roden; A J Wood; G R Wilkinson
Journal:  Pharm Res       Date:  1999-03       Impact factor: 4.200

Review 3.  Antiarrhythmic drugs: from mechanisms to clinical practice.

Authors:  D M Roden
Journal:  Heart       Date:  2000-09       Impact factor: 5.994

4.  Systemic uptake of miconazole during vaginal suppository use and effect on CYP1A2 and CYP3A4 associated enzyme activities in women.

Authors:  Mia Birkhøj Kjærstad; Flemming Nielsen; Lene Nøhr-Jensen; Stine Zwisler; Kim Brøsen; Helle Raun Andersen
Journal:  Eur J Clin Pharmacol       Date:  2010-10-06       Impact factor: 2.953

Review 5.  [Drug interactions. Mechanisms and clinical relevance].

Authors:  U Klotz; W Beil; C Gleiter; B Drewelow; E Garbe; A Gillessen; E Mutschler
Journal:  Internist (Berl)       Date:  2003-11       Impact factor: 0.743

Review 6.  Drug metabolism and ageing.

Authors:  M T Kinirons; M S O'Mahony
Journal:  Br J Clin Pharmacol       Date:  2004-05       Impact factor: 4.335

Review 7.  The role of P-glycoprotein and organic anion-transporting polypeptides in drug interactions.

Authors:  Lawrence M DuBuske
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

8.  The inhibitory effects of mitragynine on P-glycoprotein in vitro.

Authors:  Noradliyanti Rusli; Azimah Amanah; Gurjeet Kaur; Mohd Ilham Adenan; Shaida Fariza Sulaiman; Habibah Abdul Wahab; Mei Lan Tan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-01-02       Impact factor: 3.000

9.  Increased absorption of digoxin from the human jejunum due to inhibition of intestinal transporter-mediated efflux.

Authors:  Svitlana Igel; Siegfried Drescher; Thomas Mürdter; Ute Hofmann; Georg Heinkele; Heike Tegude; Hartmut Glaeser; Stefanie S Brenner; Andrew A Somogyi; Taher Omari; Christian Schäfer; Michel Eichelbaum; Martin F Fromm
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

10.  Lack of a pharmacokinetic interaction between a new smoking cessation therapy, varenicline, and digoxin in adult smokers.

Authors:  H M Faessel; A H Burstein; M D Troutman; S A Willavize; K D Rohrbacher; D J Clark
Journal:  Eur J Clin Pharmacol       Date:  2008-07-26       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.